A €4.9 million lung cancer research programme, funded by the Irish Cancer Society (ICS), has been launched today, marking the “largest single investment” in lung cancer in Ireland’s history.
This initiative led by the Beaumont RCSI Cancer Centre aims to transform lung cancer care and research, bringing state-of-the-art cancer care to the community and enhancing access to ICS support services.
Lung cancer is the leading cause of cancer-related deaths in Ireland and worldwide, killing more people every year than breast, prostate and colorectal cancer combined. Early detection is crucial to improving survival rates.
The new programme will introduce the ‘Beaumont RCSI Irish Cancer Society Lung Health Check’. This clinical trial, in collaboration with specific GP practices in north Dublin and the north east region, will invite high-risk individuals to attend community-based mobile scanning units for lung health checks.
The six-year Beaumont RCSI Irish Cancer Society Lung Outreach Programme aims to advance cancer care, focusing on early detection, advanced diagnostics, and innovative treatments.
The programme is devised and led by Prof Jarushka Naidoo, Professor of Medical Oncology at the RCSI and Consultant Medical Oncologist at Beaumont RCSI Cancer Centre.
“This programme represents a paradigm shift for lung cancer care and innovation in Ireland,” she said. “By combining the expertise of clinicians and scientists at the Beaumont RCSI Cancer Centre with vital support from the Irish Cancer Society, we will not only detect lung cancer earlier but also deliver more personalised and effective treatments.
“This funding is a critical turning point – the largest investment for lung cancer – where it is much needed, and for those at greatest risk.”
The announcement coincides with Lung Cancer Awareness Month.
Leave a Reply
You must be logged in to post a comment.